| DIRECT COMPETITOR COMPARISON | |
| YMI | AMGN | CEPH | Pvt1 | Industry | | Market Cap: | 76.50M | 58.22B | 4.65B | N/A | 168.97M | | Employees: | 24 | 16,700 | 2,780 | 11,1741 | 94 | | Qtrly Rev Growth (yoy): | -40.10% | -1.60% | 10.20% | N/A | 20.50% | | Revenue (ttm): | 3.89M | 14.58B | 2.16B | 13.42B1 | 46.74M | | Gross Margin (ttm): | -214.70% | 84.99% | 82.61% | N/A | 56.06% | | EBITDA (ttm): | -12.51M | 6.71B | 703.00M | N/A | -7.12M | | Oper Margins (ttm): | -349.73% | 38.71% | 24.96% | N/A | 2.25% | | Net Income (ttm): | -12.87M | 4.74B | 280.69M | N/A | N/A | | EPS (ttm): | -0.231 | 4.585 | 3.618 | N/A | -0.17 | | P/E (ttm): | N/A | 12.55 | 17.22 | N/A | 18.24 | | PEG (5 yr expected): | N/A | 1.35 | 0.96 | N/A | 1.07 | | P/S (ttm): | 19.81 | 3.99 | 2.16 | N/A | 4.48 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.52 | 0.00% | 58.22B | 12.55 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 53.40 | 0.00% | 15.44B | 17.87 | | Genzyme Corp. | GENZ | 49.81 | 0.00% | 13.22B | 28.40 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 43.47 | 0.00% | 39.12B | 16.81 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 52.49 | 0.00% | 9.36B | 1071.22 | | Teva Pharmaceutical Industries Limited | TEVA | 55.50 | 0.00% | 48.90B | 50.78 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 39.90 | 0.00% | 4.23B | 20.57 | | King Pharmaceuticals Inc. | KG | 12.31 | 0.00% | 3.06B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.61 | 0.00% | 5.69B | 114.17 | | Pfizer Inc. | PFE | 18.56 | 0.00% | 149.77B | 15.42 | | Johnson & Johnson | JNJ | 64.94 | 0.00% | 179.18B | 14.18 | | GlaxoSmithKline plc | GSK | 42.45 | 0.00% | 107.61B | 13.87 | | Sanofi-Aventis | SNY | 40.31 | 0.00% | 105.25B | N/A | | Novartis AG | NVS | 54.87 | 0.00% | 124.62B | 16.43 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 43.10 | 0.00% | N/A | N/A | | AstraZeneca plc | AZN | 46.62 | 0.00% | 67.60B | 9.36 | | Abbott Laboratories | ABT | 54.26 | 0.00% | 83.93B | 14.70 | | Bristol-Myers Squibb Co. | BMY | 25.85 | 0.00% | 51.21B | 13.37 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | AMGN | | 5-Star Stocks Poised to Pop: Repligen
Tue 1:45pm -
at Motley Fool | | • | CEPH | | Cephalon Sees Bullish Options Move
Tue 12:09pm -
at TheStreet.com | | • | CEPH | | Bulls Betting on Cephalon
Tue 11:07am -
at Seeking Alpha | | • | CEPH | | CEPHALON INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Tue 8:54am -
EDGAR Online | | • | AMGN | | The Cheapest Stock Around
Tue 7:00am -
at Motley Fool | | • | AMGN | | What to Do When the Dow Hits 7,500 Again
Tue 7:00am -
at Motley Fool | | • | AMGN | | 2010 Investing: A Tale of Two Economies
Mon, Dec 28 -
at Seeking Alpha | | • | AMGN | | ETFs for an Uncertain Future
Mon, Dec 28 -
at Motley Fool | | • | CEPH | | FDA Delays Nuvigil Decision
Mon, Dec 28 -
Zacks.com | | • | AMGN | | The Easiest Money You'll Ever Make
Sun, Dec 27 -
at Motley Fool | | • | CEPH | | Top 10 Stocks for Obamacare
Thu, Dec 24 -
at CNBC | | • | CEPH | | Sanofi Pulls the Plug on Two Drugs: Biotech's Latest Mishaps
Thu, Dec 24 -
at Seeking Alpha | | • | CEPH | | CEPHALON INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Tue, Dec 22 -
EDGAR Online | | • | CEPH | | A Prescription Drug for Jet Lag? Not Yet.
Tue, Dec 22 -
at The Wall Street Journal Online | | • | CEPH | | FDA extends Nuvigil jet lag review by 3 months
Mon, Dec 21 -
AP | | | All Headlines for these symbols... |
|
|
|
0.02% Nasdaq 0.00%
Competitors
